|
|
|
|
|
|
|
|
A Dynamic Approach to Industry Collaboration | | These workshops introduce an innovative approach to creating an “on-demand” interactive forum for experts from the pharmaceutical industry, academia and service/technology industries in a collaborative, non-competitive working environment. | | | Through face-to-face meetings blended into and supported by a collaborative software environment, participants will have a unique and ongoing opportunity to share information and viewpoints on optimal development, monitoring, and promotion of pharmaceutical products to minimize risk to patients, prescribers, and the industry. | | Participants will also get the opportunity to identify and interact with key collaborators, subject matter experts, valuable information sources, and industry experts working at the forefront of developing practices and new business models. | | This group will focus on the development of a “Drug Safety Body of Knowledge”, required to meet the clinical, regulatory, legal, and commercial needs of pharmaceutical companies in the years to come. | | Before the meeting, all participants are encouraged to submit short presentations of their viewpoint - their needs, their vision, their potential contribution – on the website as a form of introduction to the other participants. | | Each session will begin with short “briefing” presentations provided by experts in the field. “Background” case studies will be utilized where appropriate to support discussion. “InterAction” topics, proposed in the program but modified and expanded by the participants themselves, will be used as the basis for promoting dialog. During the meeting, participants will be able to identify and focus on the most important topics for ongoing practice enrichment, solution development, and collaboration. | | After the meeting, key presentations, case studies and follow up discussion/action outlines will be posted online in the collaboration environment which will remain a source of continuously updated information and secure communication for all qualified group members. | The InterAction amongst working groups formed at the initial meetings will continue through a series of regional (face-to-face) and regional/global virtual (web/teleconference) meetings using the online InnovationWell Collaboration Environment.
| | Top |
|
|
What we want to achieve.... | | • | Enhance the organizational appreciation and use of drug safety knowledge throughout product development and clinical use | | • | Enhance drug safety knowledge transfer to R&D teams | | • | Enhance clinical research knowledge transfer to pharmacovigilance personnel | | • | Optimize the application of new tools in drug safety-related decision making e.g., in silico modelling | | • | Manage the uncertainty in drug safety decision making |
|
|
| ...and how we’ll go about it | | • | By the formation of “Practice Enrichment” working groups aligning business partners, academia and peers on non-competitive issues | | • | Through enabling continued collaboration among participants working to identify opportunities for practice enrichment in drug safety, pharmacovigilance and risk management; share insights and recommendations in live collaboration over the web and InterAction meetings | | • | By identifying high priority actionable approaches for building the Drug Safety Body of Knowledge | | Top |
|
|
|
|
|
|
|
|
|
|
|
